Biotechnology

Aura Biosciences

Aura Biosciences to participate in BioConnect Investor Conference and Oncology Innovation Summit

Aura Biosciences released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4994 (forecast USD -0.3975)

Aura Biosciences released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3809 (forecast USD -0.4275)

Aura Biosciences released FY2025 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.7599 (forecast USD -1.9533)

Aura Biosciences released FY2025 9 Months Earnings on November 13, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.4102

Aura Biosciences released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4 (forecast USD -0.4675)

H.C. Wainwright reiterates buy rating for Aura Biosciences Inc

Aura Biosciences released FY2025 Semi-Annual Earnings on August 13 (EST), Actual Revenue: USD 0, Actual EPS: USD -1.0075

Aura Biosciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4699 (forecast USD -0.475)

Aura Biosciences Annual General Meeting Elects New Directors

HC Wainwright Raises Aura Biosciences' Rating to Buy

Official of Aura Biosciences Inc Disposes of Company Common Stock

Aura Biosciences Inc Reports Wider Quarterly Earnings Loss

Aura Biosciences released FY2025 Q1 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.5482 (forecast USD -0.492)

Aura Biosciences, Inc. Launches Underwritten Public Offering

Aura Biosciences Reports Q1 2025 Earnings and Names New Executives

Aura Biosciences reports Q1 operating expenses of 29.035 million dollars

Aura Biosciences Inc Expects EPS Loss of 49 Cents

Renaissance Technologies LLC Significantly Increased Holdings in Aura Biosciences

Aura Biosciences Inc. Bearish Positions Increase by 37.3%

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Vida Global

MetaVia

BiomX

Micware

Tradr 2X Long XNDU Daily ETF

MicroAlgo

AURA

Aura Biosciences (NASDAQ:AURA) executives presented their strategy for bel-sar, focusing on ocular oncology and non-muscle invasive bladder cancer at the H.C. Wainwright Connect Conference. The company aims to address treatment challenges in choroidal melanoma, emphasizing bel-sar's potential to preserve vision while controlling tumors. Initial data from a Phase 1b/2 study in bladder cancer is expected mid-year. The CoMpass Phase 3 trial will evaluate bel-sar's efficacy against sham treatment, with a primary endpoint of tumor progression time.

Market Beat

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences, Inc. announced inducement equity awards to its new CEO, Natalie Holles, under Nasdaq Listing Rule 5635(c)(4). The awards include stock options for 2,169,103 shares, restricted stock units for 600,118 shares, and performance-based RSUs for 553,844 shares. Vesting schedules are outlined, with options and RSUs contingent on continued service. Aura focuses on precision therapies for solid tumors and is headquartered in Boston.

StockTitan

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | AURA Stock News

Matrix Capital Management Comp sold 6,922,870 shares of Aura Biosciences (NASDAQ:AURA) at an average price of $5.64, totaling approximately $39 million. This transaction was disclosed in a filing with the SEC. Aura Biosciences has a market cap of $525.80 million and reported a quarterly EPS of ($0.50), missing estimates. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and an average target price of $21.50. The company focuses on developing novel therapies for cancer treatment.

Mercadolibre

Matrix Capital Management Comp Sells 6,922,870 Shares of Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences (NASDAQ:AURA) is set to release its Q1 2026 earnings on May 14, with analysts expecting a loss of $0.40 per share. The company previously reported a loss of $0.37 per share, exceeding estimates. The stock is currently priced at $8.40, with a market cap of $539.28 million. Insider trading activity has seen significant share sales, and institutional investors hold 96.75% of the stock. Analyst ratings vary, with a consensus rating of "Hold" and a target price of $21.50.

Invesco

Ameriprise Financial

Aura Biosciences (AURA) to Release Earnings on Thursday

Aura Biosciences has completed a public offering of 39,591,000 common shares at $6.00 and pre-funded warrants for 3,800,000 shares at $5.99999, netting approximately $280.8 million. The offering, underwritten by Leerink Partners, TD Securities, and Evercore, closed on May 5, 2026. The company plans to allocate $241.8 million to advance clinical programs and general corporate purposes, while $39.0 million will be used to repurchase shares from Matrix at $5.64 each.

TradingView

Toronto Dominion Bank

Evercore

Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | AURA Stock News

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | AURA Stock News

Aura Biosciences(AURA.US)

Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | AURA Stock News

Matrix Capital Management Comp Sells 6,922,870 Shares of Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences (AURA) to Release Earnings on Thursday

Aura Biosciences Prices Equity Offering, Nets $280.8 Million; Underwritten by Leerink, TD, Evercore

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares | AURA Stock News